Log In
BCIQ
Print this Print this
 

VX-353

  Manage Alerts
Collapse Summary General Information
Company Vertex Pharmaceuticals Inc.
DescriptionPolymerase inhibitor that targets the influenza A virus
Molecular Target Viral polymerase
Mechanism of ActionViral polymerase inhibitor
Therapeutic Modality 
Latest Stage of DevelopmentPhase II
Standard IndicationInfluenza virus
Indication DetailsTreat influenza A infection
Regulatory Designation
PartnerJohnson & Johnson

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

$30.0M

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

06/18/2014

Undisclosed

$30.0M

Undisclosed

Get a free BioCentury trial today